Desai RJ, et al. - Rheumatoid arthritis (RA) patients receiving tofacitinib were compared with those receiving tumor necrosis factor (TNF) inhibitors for the risk of venous thromboembolism (VTE). From the Truven and Medicare databases, researchers identified a total of 34,074 RA patients (mean age 50 years; 5.6% tofacitinib initiators) and 17,086 RA patients (mean age 71 years; 5.8% tofacitinib initiators), respectively. As per propensity score–adjusted HRs, tofacitinib-treated and TNF inhibitor–treated patients showed no significant differences in the risk of VTE in either database, with a pooled HR of 1.33. In a total of 50,865 RA patients initiating treatment with tofacitinib or a TNF inhibitor, VTE occurred infrequently (<1 per 100 person-years). RA patients receiving tofacitinib showed a numerically higher, but statistically nonsignificant, risk of VTE vs those receiving TNF inhibitors.